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OBJECTIVE — Initial treatment with antidepressant medication is insufﬁciently effective in
some patients with type 2 diabetes, and factors predicting treatment outcome are poorly
understood.
RESEARCH DESIGN AND METHODS — Aggregate data from two published trials
were analyzed to determine the rates and predictors of response to antidepressant pharmaco-
therapy in adults with type 2 diabetes using conventional markers of initial treatment outcome
(improvement, response, partial remission, and remission). Three hundred eighty-seven pa-
tients who received up to 16 weeks of open-label, acute-phase treatment using bupropion (n 
93) or sertraline (n  294) were studied. Logistic regression was used to identify predictors of
poor treatment outcome. Candidate predictors included age, race, sex, initial Beck Depression
Inventory (iBDI) score, treatment received (sertraline or bupropion), family history of depres-
sion, extant diabetes complications (eDC), and A1C level.
RESULTS — Of 387 patients initiated on treatment, 330 (85.3%) met criteria for improve-
ment, 232 (59.9%) for response, 207 (53.5%) for partial remission, and 179 (46.3%) for full
remission. Signiﬁcant independent predictors of poor outcome included eDC (for no improve-
ment); sertraline treatment, eDC, and younger age (for nonresponse); sertraline treatment, eDC,
and higher iBDI (for failure to partially remit); and younger age and higher iBDI (for failure to
fullyremit).Higherpainscorespredictedthreeofthefourmarkersofpooroutcomeinthesubset
with pain data.
CONCLUSIONS — In patients with type 2 diabetes, poor initial response to antidepressant
medication is predicted by multiple factors. Auxiliary treatment of pain and impairment may be
required to achieve better outcomes.
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C
linically signiﬁcant depression of-
ten occurs in the context of medi-
cal illness. It is present in one of
every four patients with diabetes (1), is
highly recurrent (2), and imposes addi-
tional risks of poor diabetes self-care,
hyperglycemia (3), diabetes complica-
tions (4), and death (5). Randomized
controlled trials demonstrate the efﬁ-
cacy of pharmacotherapy (6–8), cogni-
tive behavior therapy (CBT) (9), and
stepped, collaborative care treatments
(10) for major depressive disorder
(MDD) in patients with diabetes. Relief
of depression symptoms, however, of-
ten is incomplete and leaves the patient
at risk of relapse or recurrence of MDD.
Improvement in mood is associated
with improvement in glycemic control
in many but not all of these trials. Small
depression treatment effects limit the
ability to study this question, and this
has fueled interest in efforts to improve
the potency of depression treatment.
Research to identify predictors of re-
sponse to antidepressant treatment in
psychiatric samples has been inconclu-
sive. Methodological issues including small
sample size, sample heterogeneity, variable
deﬁnitions of depression treatment re-
sponse, inadequate diagnostic speciﬁcity,
and suboptimal statistical methods have
limited the reproducibility and generaliz-
abilityofpreviousﬁndings(11).Researchof
this kind in individuals with diabetes is
scant. In a controlled trial of CBT for MDD
in 42 adults with type 2 diabetes, Lustman
et al. (12) found that factors pertaining to
diabetes management (poor adherence to
glucosemonitoringinstructions)andsever-
ity (higher glycosylated hemoglobin levels,
presence of diabetes complications) were
independent predictors of poor treatment
outcome.
Recent antidepressant trials in nondi-
abetic samples suggest that up to 70% of
patientsdonotrespondadequatelytoini-
tial pharmacotherapy (13). Similarly, the
prognosis of depression in diabetes sam-
ples is guarded, even following successful
treatment. Of those who achieve recov-
ery,one-thirdsufferarecurrencewithina
year (8) and 10% remain depression
free for 5 years (2). As a step toward the
goal of improving depression treatment
outcome,theaimofthepresentstudywas
to identify the rates and predictors of ini-
tialresponsetoantidepressantpharmaco-
therapy in people with diabetes.
RESEARCH DESIGN AND
METHODS— This report presents a
secondaryanalysisofacute-phasedataag-
gregated from two previously published
treatment trials of pharmacotherapy for
MDD in adults with diabetes. The pur-
pose, design, and ﬁndings from these two
studies are described in detail elsewhere
(8,14) and are summarized here. The ﬁrst
study was a multicenter, randomized,
placebo-controlled trial of sertraline for
prevention of MDD recurrence in adults
with type 1 or type 2 diabetes (8). Collab-
orating sites included Washington Uni-
versity in St. Louis, the University of
Arizona in Tucson, and the University of
Washington in Seattle. The second study
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri; the
2Department of Medicine, Washington University School of Medicine, St. Louis, Missouri; and the
3Department of Veterans Affairs Medical Center, St. Louis, Missouri.
Corresponding author: Patrick J. Lustman, lustmanp@wustl.edu.
Received 6 August 2009 and accepted 12 December 2009. Published ahead of print at http://care.
diabetesjournals.org on 23 December 2009. DOI: 10.2337/dc09-1466.
© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Clinical Care/Education/Nutrition/Psychosocial Research
ORIGINAL ARTICLE
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 3, MARCH 2010 485was a single-site (Washington University
in St. Louis) trial of bupropion for MDD
in adults with type 2 diabetes (14). Inclu-
sion in the aggregate analysis was limited
to patients with type 2 diabetes, as the
bupropion trial had included only those
patients and excluded those with type 1
diabetes. Open treatment with antide-
pressantmedicationwasprovidedtosub-
jects in both studies during the initial
(acute) phase, the goal of acute treatment
being induction of depression remission.
Written informed consent was obtained
from all subjects before evaluation, and
theinstitutionalreviewboardateachpar-
ticipating site reviewed and approved the
trials. Both studies were two-phase de-
pression treatment trials that included an
acute (induction) and maintenance
phase.Analysisanddiscussioninthecur-
rent report is based upon the acute-phase
ﬁndings. The length of the acute phase
was 16 weeks for the sertraline trial and
10 weeks for the bupropion trial.
The two studies utilized similar eligi-
bility criteria and enrolled patients who
were aged 18–80 years, had diagnoses of
type 1 or type 2 diabetes and MDD, and
haddepressionsymptomsofatleastmod-
erate severity, as indicated by a total score
of14ontheBeckDepressionInventory
(version I) (BDI) (15). Patients were ex-
cludedfromparticipationiftheyhadac-
tive suicidal or homicidal ideation, a
priorsuicideattempt,currentsubstance
abuse, a history of psychotic or bipolar
disorder, or a contraindication to the
study medication.
Assessment and monitoring during
treatment
The presence of MDD was determined by
structured psychiatric interview and con-
formed to the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition
(DSM-IV) criteria (16). The BDI (15)
and Hamilton Depression Rating Scale
(HDRS) (17) were used to assess the se-
verity of depression symptoms. Demo-
graphic information (age, sex, race,
marital status, and education level), his-
tory of depression treatment, family his-
tory of depression, and diabetes
characteristics (age of onset, method of
treatment, and the presence of diabetes
complications including neuropathy, ret-
inopathy, nephropathy, hyperlipidemia,
and atherosclerosis [coronary artery dis-
ease, cerebrovascular disease, peripheral
vascular disease]) were obtained using a
combination of patient self-report, phys-
icalexam,andareviewofclinicalrecords.
Eligible,consentingparticipantswere
enrolled and open treatment with a stan-
dardized dosage of antidepressant medi-
cation (50 mg/day for sertraline and 150
mg/day for bupropion) was initiated fol-
lowing completion of the baseline evalu-
ation. The dosage was adjusted biweekly
(to a maximum of 200 mg/day for sertra-
line and 450 mg/day for bupropion) de-
pending on clinical response and adverse
events. Patients taking an antidepressant
at the time of study enrollment were ta-
pered off the medication over an interval
of 2 weeks while sertraline or bupro-
pion was introduced.
Patients were seen every 2 weeks at
ofﬁce visits. The BDI and HDRS were ad-
ministered at each visit. Glycemic control
(A1C) (18) was measured at baseline and
the end of the acute phase. Health-related
quality of life was assessed at these points
with the Short Form-36 Health Survey
(SF-36) (19). The SF-36 includes a sub-
scale that measures the severity and im-
pact of bodily pain.
Deﬁnitions of treatment outcome
Rates of response were calculated accord-
ing to the intention-to-treat principle and
to conventional depression treatment
outcome descriptors (improvement, re-
sponse, partial remission, and full remis-
sion). Deﬁnitions of these outcomes were
made in accordance with the DSM-IV
section on episode speciﬁers for mood
disorders (16) and operational criteria
recommendations by Riso et al. (20) and
the American College of Neuropsychop-
harmacology Task Force on Conceptual-
izing Response and Remission in MDD
(21). Response was deﬁned as a 50%
reduction in BDI total score from baseline
to the end of the acute phase. Partial re-
mission was deﬁned as a BDI score of 9
at the end of the acute phase. Full remis-
sion was deﬁned as a BDI score of 9 for
a period of 4 weeks prior to the end of the
acute phase. No improvement catego-
rized those whose depression severity did
notchangeorworsenedduringthecourse
of treatment and was deﬁned as an end of
acute phase BDI score 100% of the
baseline BDI score. The categories are not
mutually exclusive; a given patient may
meet criteria for any one, any combina-
tion, or all four favorable outcomes. For
example, a patient having a BDI score of
15atentryand8attheendofacutephase
(with that degree of improvement limited
to the preceding 2 weeks) would meet
criteria for improvement and partial
remission.
Statistical analysis
Logistic regression analysis was used
to determine signiﬁcant (P  0.05) pre-
dictors of poor depression treatment
outcome (i.e., no improvement, nonre-
sponse, nonpartial remission, and non-
full remission) in order to identify factors
that might themselves be targets of inter-
vention. Candidate predictors were de-
rived from the depression treatment
literature in diabetes (12) and psychiatric
samples (11). A correlational matrix was
constructed to identify highly correlated
(r0.40)variables;inoneinstancewhen
this occurred (baseline BDI and HDRS to-
talscores,r0.59),initialBDI(iBDI)was
included in the main regression model.
The ﬁnal model included demographic
(age, race, and sex), depression (treat-
ment type [sertraline versus bupropion],
iBDI, and family history of depression),
and diabetes (A1C, presence of any dia-
betes complications) variables. While the
study lacked the statistical power to parse
the unique contribution of each diabetes
complication to depression treatment
outcome, the presence of increasing com-
plications is a proxy for severity of symp-
tomatic diabetes. An “Enter” method was
used for the variable input in all regres-
sion analyses. For those patients who
dropped out before completing the acute
phase, a last-observation-carried-forward
method was used. Positive predictive val-
ues for nonremission and nonimprove-
ment were calculated as the proportion of
true positives over the sum of true posi-
tives plus false-positives.
A logistic regression analysis was also
performed in the subgroup (n  267)
with data on pain severity and impact
(SF-36bodilypainscalescore),sleepdys-
function (aggregate score from the three
HDRS sleep questions), and self-reported
historyofdepressiontreatment.Thissub-
group analysis added the variables of
pain, sleep, and prior depression treat-
ment to those used in the main model to
determine additional predictors of poor
treatment outcome.
RESULTS— Three hundred eighty-
seven patients received up to 16 weeks of
open-label, acute-phase treatment for
MDD. Two hundred ninety-four (76.0%)
patients were treated with sertraline, and
93 (24.0%) received bupropion. Demo-
graphic, diabetes, depression, and other
clinical characteristics of the sample are
presented in Table 1. Overall, 330
(85.3%) of 387 patients evidenced some
degree of symptomatic improvement and
Predictors of antidepressant response
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Two hundred and seven (53.5%) patients
achieved partial remission and 179
(46.3%) achieved full remission.
The results of the logistic regression
analysesarepresentedinTable2.Thesig-
niﬁcantpredictorofnoimprovementwas
extant diabetes complications (odds ratio
[OR] 2.75 [95% CI 1.24–6.11]; P 
0.01). Predictors of nonresponse were
treatment with sertraline (2.47 [1.39–
4.41]; P  0.002), extant diabetes com-
plications (eDC) (2.27 [1.37–3.76];
P  0.001), and younger age (1.03
[1.01–1.05]; P  0.009). Predictors of
nonpartial remission included sertra-
line treatment (2.80 [1.59–4.94]; P 
0.001), eDC (2.04 [1.25–3.34]; P 
0.005), and higher iBDI (1.06 [1.03–
1.09]; P  0.001), while predictors of
nonfullremissionwereyoungerage(1.02
[1.00–1.05]; P  0.04) and higher iBDI
(1.06 [1.03–1.09]; P  0.001).
The cumulative contribution of any
eDC, younger age (50 years), and
higheriBDIscore(23)onthepredictive
value of nonimprovement and nonremis-
sion was examined (Fig. 1). With an in-
creasing number of these features, the
likelihood of poor depression treatment
outcome increased linearly. Whereas pa-
tients with none of the features had
25% likelihood of failing depression
treatment, subjects with any one feature
hadanearly50%chanceofnotremitting.
Patients with all three features were at the
highest risk of poor treatment outcome as
68% of them did not remit, and nearly
20% did not improve.
Subgroup analysis
Logistic regression analysis was per-
formed in the subgroup (n  267) with
data on pain severity and impact, sleep
dysfunction, and prior depression treat-
ment. Of these three factors, higher pain
scores emerged as the only signiﬁcant
predictor, and it predicted three of four
measures of poor outcome: nonresponse
(OR 1.18 [95% CI 1.04–1.35]; P 
0.009), nonpartial remission (1.23
[1.08–1.39]; P  0.001), and nonremis-
sion (1.25 [1.11–1.42]; P  0.001). The
other predictors found in the main anal-
ysis remained the same for the subgroup,
exceptthatyoungeragewasnolongersig-
niﬁcant in the nonresponse and nonfull
remission models.
CONCLUSIONS — The primary pur-
pose of this study was to identify pre-
dictors of initial depression treatment
outcome in patients with type 2 diabetes,
information that could help clinicians
identify and manage those at greatest risk
of nonresponse. A multivariate set of pre-
dictors comprised of epidemiological, di-
abetes, and depression characteristics
wereidentiﬁed.Theseincludedextantdi-
abetes complications, sertraline treat-
ment, higher iBDI, younger age, and, in
subgroup analyses, higher pain scores.
Our ﬁndings afﬁrm reports that more
severediabetesportendspoorresponseto
depression treatment (12). The presence
of complications predicted three of four
measures of nonresponse and was the
only predictor of treatment resistance de-
ﬁned as no decrease in depression symp-
tom severity during treatment. In the
present report, baseline A1C (mean 
8.3  2.1%) did not predict depression
treatment outcome as it had in a previous
study (12), a ﬁnding potentially attribut-
able to greater variance in baseline A1C
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Table 1—Demographic, diabetes, depres-
sion, and other clinical characteristics of the
sample
n 387
Age (years) 53.0  11.1
Female sex 234 (60.5)
Caucasian race 272 (70.3)
Married 209 (54.0)
Education (years) 13.5  2.9
Age of diabetes onset (years) 45.2  11.6
Duration of diabetes (years) 7.1  7.3
Any diabetes complications 247 (63.8)
Neuropathy 157 (40.6)
Nephropathy 32 (8.3)
Retinopathy 63 (16.3)
Atherosclerosis 60 (15.5)
Hyperglycemia 146 (37.7)
Diabetes management —
Diet only 42 (10.9)
Insulin 76 (19.6)
Oral agent 197 (50.9)
Insulin and oral agent 61 (15.8)
A1C at baseline (%) 8.31  2.1
A1C at end of acute phase (%) 7.70  1.8
No improvement 57 (14.7)
Responders 232 (59.9)
Partial remitters 207 (53.5)
Full remitters 179 (46.3)
Family history of depression 203 (52.5)
Prior depression treatment 209 (54.0)
BDI at baseline 24.6  8.2
BDI at end of acute phase 9.2  8.7
Bodily pain* 6.5  2.4
Sleep† 2.7  1.8
Data are means  SD or n (%). *Mean SF-36 scale
score. †Mean aggregate score from the three HDRS
questions on sleep dysfunction.
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study. Poor compliance with blood glu-
cose monitoring has been shown to pre-
dict nonremission of MDD with cognitive
behavior therapy, but unfortunately, it
was not measured in the current trial.
This study was designed to identify
predictors of initial depression treatment
response and was not designed to assess
the efﬁcacy or effectiveness of speciﬁc an-
tidepressants. Nonetheless, treatment
(sertraline or bupropion) was one of the
variables included in the regression
model, and sertraline emerged as a signif-
icant predictor of poor outcome. A ran-
domized, controlled trial would be
required to truly determine the compara-
tive effectiveness of these medications.
More severe depression at trial entry
(higher iBDI) predicted failure to achieve
partial remission and full remission, a
ﬁndingreportedinsome(22),butnotall,
depressiontreatmenttrials(11).Ahistory
of prior episodes or treatment of depres-
sion,whilepredictiveofpooroutcomesin
psychiatric samples (11), did not predict
anyofthefourtreatmentoutcomesinour
study. While reliable methods for deter-
mination of MDD have been available for
some time, less attention has been paid to
measurement of MDD history and dura-
tion. Precise calculation of cumulative time
spentinMDDmaybeanimportantelement
in the assessment. In a 10-year prospective
study of children with type 1 diabetes, Ko-
vacs et al. (23) found that cumulative time
spent in depression and in poor glycemic
control each independently predicted de-
velopment of retinopathy.
Age has not been a reliable predictor
of depression treatment outcome in psy-
chiatric samples. In diabetic patients,
Williams et al. (24) reported that younger
patients were more likely to relapse dur-
ing the maintenance phase of depression
treatment. Younger age also predicted
poor outcome (nonresponse and nonre-
mission) in the present study. Patients
with chronic medical illnesses tend to be
older than those typically enrolled in an-
tidepressant trials, and this may help to
explain the discrepant ﬁndings in the di-
abetes and psychiatric literatures.
In the subgroup analysis, higher pain
scores predicted three of the four mea-
suresofpoortreatmentoutcome.Chronic
pain is commonly comorbid with depres-
sion, and our analysis adds to mounting
evidenceinnondiabeticsamplesthatpain
hasanegativeimpactondepressiontreat-
ment course (25). Pain, measured in this
studywiththeSF-36,isacompositescore
reﬂecting both severity and functional
limitations associated with pain. The
presence of pain and functional impair-
ment may help identify those at risk for
poor depression treatment outcome.
Ourstudyissubjecttothelimitations
of secondary analyses with combined
datasets, and the ﬁndings warrant pro-
spective replication. While method-
ologically similar in most regards (e.g.,
methods for diagnosing and measuring
depression and change in depression se-
verity), the interval covering acute treat-
ment was longer in the sertraline versus
bupropion trial (16 vs. 10 weeks, respec-
tively). While this would appear to favor
sertraline by allowing subjects more time
to respond, rates of response were uni-
formly lower in sertraline- versus bupro-
pion-treatedpatients.Theextenttowhich
our ﬁndings may be generalized to pa-
tients with type 1 diabetes is unclear. The
aggregate analysis was limited to patients
with type 2 diabetes because of the small
number and disproportionate distribu-
tion of type 1 diabetic patients in the two
trials(n57,allfromthesertralinetrial).
In exploratory analyses that included
both patients with type 1 as well as those
withtype2diabetes(n444),thefactors
that predicted treatment response were
unchanged from those found when the
analyses were limited to patients with
type 2 diabetes. While the study design is
desirable from the standpoint of external
validity, it cannot apportion response as
related to nonspeciﬁc versus direct med-
ication effect. Finally, the modest propor-
tion of variance explained by the logistic
regression models (6–15%) underscores
the need to study novel predictors and
predictive models.
In summary, our results indicate that
response to depression treatment in type
2 diabetes is inﬂuenced by a multidimen-
sional set of factors. Physical disease
markers, initial depression severity, de-
mographic, and other clinical variables
are relevant to the course of depression
treatment, as is perhaps the choice of an-
tidepressant agent. These predictors may
serve as targets for intervention and ave-
nues for further research, steps toward
personalized mental health care and im-
proved patient outcomes.
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